Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality

American Journal of Cardiology

Volumn 94, Issue 2, 2004, Pages 190-192

  Rajagopal, Vivek ^b   Gurm, Hitinder S ^b   Bhatt, Deepak L ^a   Lincoff, A Michael ^b   Tcheng, James E ^b   Kereiakes, Dean J ^b   Kleiman, Neal S ^b   Jia, Gang ^b   Topol, Eric J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SCREENING; EVALUATION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORTALITY; OUTCOMES RESEARCH; PATIENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 3142566624     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.03.060     Document Type: Article

References (19)

1. Bhatt D.L., Topol E.J. Need to test the arterial inflammation hypothesis. Circulation. 106:2002;136-140
2. Alexander R.W. Inflammation and coronary artery disease. N Engl J Med. 331:1994;468-469
3. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143
4. Ridker P.M., Morrow D.A. C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 21:2003;315-325
5. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J.R., Pepys M.B. Low grade inflammation and coronary heart disease prospective study and updated meta-analyses. BMJ. 321:2000;199-204
6. Chew D.P., Bhatt D.L., Robbins M.A., Penn M.S., Schneider J.P., Lauer M.S., Topol E.J., Ellis S.G. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 104:2001;992-997
7. Bhatt D.L., Chew D.P., Lincoff A.M., Simoons M.L., Harrington R.A., Ommen S.R., Jia G., Topol E.J. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 92:2003;136-140
8. Yen M.H., Bhatt D.L., Chew D.P., Harrington R.A., Newby L.K., Ardissino D., Van de Werf F., White J.A., Moliterno D.J., Topol E.J. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med. 115:2003;318-321
9. Blake G.J., Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 41:2003;37S-42S
10. Brown D.W., Giles W.H., Croft J.B. White blood cell count an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol. 54:2001;316-322
11. Gurm H.S., Bhatt D.L., Lincoff A.M., Tcheng J.E., Kereiakes D.J., Kleiman N.S., Jia G., Topol E.J. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention insights from EPIC, EPILOG, and EPISTENT trials. Heart. 89:2003;1200-1204
12. Gurm H.S., Bhatt D.L., Gupta R., Ellis S.G., Topol E.J., Lauer M.S. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Heart J. 146:2003;692-698
13. Serrano C.V. Jr, Ramires J.A., Venturinelli M., Arie S., D'Amico E., Zweier J.L., Pileggi F., da Luz P.L. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 29:1997;1276-1283
14. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-961
15. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696
16. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92
17. Rahel B.M., Visseren F.L., Suttorp M.J., Plokker T.H., Kelder J.C., de Jongh B.M., Bouter K.P., Diepersloot R.J. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 60:2003;136-140
18. Aggarwal A., Schneider D.J., Terrien E.F., Gilbert K.E., Dauerman H.L. Increase in interleukin-6 in the first hour after coronary stenting an early marker of the inflammatory response. J Thromb Thrombolysis. 15:2003;25-31
19. Almagor M., Keren A., Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J. 145:2003;248-253